Azetidines as MEK inhibitors for the treatment of proliferative diseases
US8362002B2 · kind B2 · utility
7Cited by
6References
63Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 15, 2011 |
| Grant date | Jan 29, 2013 |
| Priority date | — |
| Expiry date | Mar 15, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.